Compare Abbott Laboratories (ABT) vs DoorDash Inc (DASH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs DoorDash Inc — how do they compare? Abbott Laboratories trades at $95.18 (market cap $166.94B), while DoorDash Inc trades at $186.94 (market cap $85.28B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays a 2.63% dividend while DoorDash Inc pays none. Which is the better fit depends on your goals.
| ABT | DASH | |
|---|---|---|
Market Cap | $166.94B | $85.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $281.74 |
52-Week Low | $82.57 | $146.60 |
Enterprise Value | $193.69B | $83.03B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
DoorDash (DASH) trades at $195.72, up 1.93% today, with a bullish technical signal and strong analyst consensus. Revenue grew to $13.72B in 2025, with net income reaching $935M, though recent quarters show mixed earnings performance. The stock is near resistance at $200, with RSI indicating overbought conditions. Recent news highlights AI initiatives and market dominance.
Outlook remains positive with a $231.50 consensus price target, but risks include competition and high valuation multiples. Earnings growth and international expansion are key catalysts, while inflation and execution challenges pose headwinds for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →
